The Bio/Pharma Beat

    View Author November 2019

    We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from October 2019, including:

    • The Federal Circuit holds the “hope” that a potentially promising drug will treat a particular cancer is not enough to establish a reasonable expectation of success
    • The Federal Circuit holds a method of treating hepatitis C with a genus of compounds invalid for lack of enablement and written description
    • California enacts a “pay for delay” law